Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry

被引:10
作者
Lennon, P. [1 ]
Deady, S. [2 ]
White, N. [3 ]
Lambert, D. [3 ]
Healy, M. L. [4 ]
Green, A. [3 ]
Kinsella, J. [1 ]
Timon, C. [1 ]
O'Neill, J. P. [5 ]
机构
[1] St James Hosp, Dept Otolaryngol Head & Neck Surg, Dublin 8, Ireland
[2] Natl Canc Register, Cork, Ireland
[3] Our Ladys Childrens Hosp, Dept Clin Genet, Crumlin, Ireland
[4] St James Hosp, Dept Endocrinol, Dublin 8, Ireland
[5] Beaumont Hosp, Dept Otolaryngol Head & Neck Surg, Dublin, Ireland
关键词
Medullary thyroid cancer; Database; Survival; Cancer registry; RET proto-oncogene; Calcitonin; PROGNOSTIC-FACTORS; RET PROTOONCOGENE; BIOCHEMICAL CURE; CLINICAL-CHARACTERISTICS; MULTIVARIATE-ANALYSIS; SOMATIC MUTATIONS; FOLLOW-UP; CARCINOMA; SURVIVAL; MANAGEMENT;
D O I
10.1007/s11845-016-1455-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Medullary thyroid cancer consists of a spectrum of disease that ranges from extremely indolent tumors to aggressive types associated with a high mortality rate. The objective of our study is to evaluate the prognostic factors and outcomes of patients diagnosed with MTC in a homogenous population, and to examine patients diagnosed with MTC for mutations in the RET proto-oncogene from the same period. Methods A retrospective analysis of the National Cancer Registry in Ireland was undertaken, between 1998 and 2007. The Kaplan-Meier method was used to determine overall survival and factors predictive of outcome were determined by univariate and multivariate analysis by cox regression using Stata 13 software. Main findings Forty-three patients were diagnosed with medullary thyroid cancer, 55.8 % were female and 44.2 % were male. A median age of 52 was found. The overall median survival was 6.32 years and the 1-and 5-year overall survival was 88.37 and 62.79 %, respectively, with 10-year survival calculated at 48.63 %. On univariate analysis age, stage and surgical intervention were statistically significant indicators of prognosis. T stage and age remained statistically significant indicators of prognosis on multivariate analysis. Two patients with no history of MENsyndromes or family history of medullary thyroid cancer had RET proto-onocogene mutations. Conclusions Our patient cohort was substantially older and presented at an advanced T status than what is commonly seen in the literature. This may account for poor survival outcomes and the very low pick-up of RET mutations in sporadic medullary thyroid cancer.
引用
收藏
页码:89 / 95
页数:7
相关论文
共 52 条
[1]   Association of NOD2 with Crohn's disease in a homogenous Irish population [J].
Bairead, E ;
Harmon, DL ;
Curtis, AM ;
Kelly, Y ;
O'Leary, C ;
Gardner, M ;
Leahy, DT ;
Vaughan, P ;
Keegan, D ;
O'Morain, C ;
O'Donoghue, D ;
Shanahan, F ;
Parfrey, NA ;
Quane, KA .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2003, 11 (03) :237-244
[2]   Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma [J].
Balentine, Courtney J. ;
Chen, Herbert .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) :7-8
[3]   Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].
Barbet, J ;
Campion, L ;
Kraeber-Bodéré, F ;
Chatal, JF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6077-6084
[4]  
BERGHOLM U, 1990, ACTA CHIR SCAND, V156, P37
[5]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[6]   Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control [J].
Brierley, J ;
Tsang, R ;
Simpson, WJ ;
Gospodarowicz, M ;
Sutcliffe, S ;
Panzarella, T .
THYROID, 1996, 6 (04) :305-310
[7]   The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer [J].
Chen, Herbert ;
Sippel, Rebecca S. ;
O'Dorisio, M. Sue ;
Vinik, Aaron I. ;
Lloyd, Ricardo V. ;
Pacak, Karel .
PANCREAS, 2010, 39 (06) :775-783
[8]   Prognostic variables and calcitonin in medullary thyroid cancer [J].
Clark, JR ;
Fridman, TR ;
Odell, MJ ;
Brierley, J ;
Walfish, PG ;
Freeman, JL .
LARYNGOSCOPE, 2005, 115 (08) :1445-1450
[9]   Long-term clinical and biochemical follow-up in medullary thyroid carcinoma -: A single institution's experience over 20 years [J].
Cupisti, Kenko ;
Wolf, Achim ;
Raffel, Andreas ;
Schott, Matthias ;
Miersch, Daniel ;
Yang, Qin ;
Eisenberger, Claus F. ;
Roeher, Hans D. ;
Knoefel, Wolfram T. .
ANNALS OF SURGERY, 2007, 246 (05) :815-821
[10]   Determinants of life expectancy in medullary thyroid cancer: age does not matter [J].
de Groot, Jan Willem B. ;
Plukker, John T. M. ;
Wolffenbuttel, Bruce H. R. ;
Wiggers, Theo ;
Sluiter, Willem J. ;
Links, Thera P. .
CLINICAL ENDOCRINOLOGY, 2006, 65 (06) :729-736